株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

治療抵抗性鬱病:パイプライン製品の分析

Treatment Resistant Depression - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 302486
出版日 ページ情報 英文 74 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
治療抵抗性鬱病:パイプライン製品の分析 Treatment Resistant Depression - Pipeline Review, H2 2016
出版日: 2016年10月26日 ページ情報: 英文 74 Pages
概要

治療抵抗性鬱病(TRD)は、抗鬱剤が効かない、大鬱病性障害の発作です。集中力の欠如、疲労、不眠症、過食や食欲不振、持続的な痛み、頭痛、けいれん、消化器の異常などの症状が生じます。

当レポートでは、治療抵抗性鬱病に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

治療抵抗性鬱病の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

治療抵抗性鬱病:企業で開発中の治療薬

治療抵抗性鬱病:大学/機関で研究中の治療薬

治療抵抗性鬱病:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

治療抵抗性鬱病:企業で開発中の製品

治療抵抗性鬱病:大学/機関で研究中の製品

治療抵抗性鬱病の治療薬開発に従事している企業

  • Addex Therapeutics Ltd
  • Amorsa Therapeutics Inc.
  • Axsome Therapeutics, Inc.
  • Johnson & Johnson
  • 大塚ホールディングス

治療抵抗性鬱病:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

治療抵抗性鬱病:最近のパイプライン動向

治療抵抗性鬱病:休止中のプロジェクト

治療抵抗性鬱病:開発が中止された製品

治療抵抗性鬱病:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8591IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Treatment Resistant Depression - Pipeline Review, H2 2016, provides an overview of the Treatment Resistant Depression (Central Nervous System) pipeline landscape.

Treatment resistant depression (TRD) is an episode of major depressive disorder that does not respond to an antidepressant medication. Symptoms include difficulty concentrating, fatigue, insomnia, overeating or appetite loss and persistent aches or pains, headaches, cramps, or digestive problems. Treatment includes antidepressant from a different drug class, antipsychotic medication, electroconvulsive therapy (ECT) and vagus nerve stimulation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Treatment Resistant Depression - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Treatment Resistant Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Treatment Resistant Depression (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Treatment Resistant Depression and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 4 and 6 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively for Treatment Resistant Depression.

Treatment Resistant Depression (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Treatment Resistant Depression (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Treatment Resistant Depression (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Treatment Resistant Depression (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Treatment Resistant Depression (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Treatment Resistant Depression (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Treatment Resistant Depression (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Treatment Resistant Depression (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Treatment Resistant Depression Overview
  • Therapeutics Development
    • Pipeline Products for Treatment Resistant Depression - Overview
    • Pipeline Products for Treatment Resistant Depression - Comparative Analysis
  • Treatment Resistant Depression - Therapeutics under Development by Companies
  • Treatment Resistant Depression - Therapeutics under Investigation by Universities/Institutes
  • Treatment Resistant Depression - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Treatment Resistant Depression - Products under Development by Companies
  • Treatment Resistant Depression - Products under Investigation by Universities/Institutes
  • Treatment Resistant Depression - Companies Involved in Therapeutics Development
    • Addex Therapeutics Ltd
    • Amorsa Therapeutics Inc.
    • Avanir Pharmaceuticals, Inc.
    • Axsome Therapeutics Inc
    • Biohaven Pharmaceutical Holding Company Limited
    • Eli Lilly and Company
    • Evotec AG
    • Johnson & Johnson
    • Otsuka Holdings Co., Ltd.
    • Relmada Therapeutics, Inc.
    • Reviva Pharmaceuticals Inc.
    • Sumitomo Dainippon Pharma Co., Ltd.
    • Takeda Pharmaceutical Company Limited
  • Treatment Resistant Depression - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (bupropion hydrochloride + dextromethorphan hydrobromide) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (dextromethorphan + quinidine sulfate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AMS-410 FA - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AMS-520 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVP-786 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CX-157 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DSP-1200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • esketamine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EVT-100 Series - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-341495 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • REL-1017 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • riluzole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Insomnia, Obesity and Treatment Resistant Depression - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize mGluR2 for Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-653 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VU-0431316 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Treatment Resistant Depression - Dormant Projects
  • Treatment Resistant Depression - Discontinued Products
  • Treatment Resistant Depression - Product Development Milestones
    • Featured News & Press Releases
      • Mar 17, 2016: Axsome Therapeutics Initiates Phase 3 Study of AXS-05 for Treatment Resistant Depression
      • Sep 03, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
      • Aug 14, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Treatment Resistant Depression, H2 2016
  • Number of Products under Development for Treatment Resistant Depression - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Treatment Resistant Depression - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Treatment Resistant Depression - Pipeline by Amorsa Therapeutics Inc., H2 2016
  • Treatment Resistant Depression - Pipeline by Avanir Pharmaceuticals, Inc., H2 2016
  • Treatment Resistant Depression - Pipeline by Axsome Therapeutics Inc, H2 2016
  • Treatment Resistant Depression - Pipeline by Biohaven Pharmaceutical Holding Company Limited, H2 2016
  • Treatment Resistant Depression - Pipeline by Eli Lilly and Company, H2 2016
  • Treatment Resistant Depression - Pipeline by Evotec AG, H2 2016
  • Treatment Resistant Depression - Pipeline by Johnson & Johnson, H2 2016
  • Treatment Resistant Depression - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
  • Treatment Resistant Depression - Pipeline by Relmada Therapeutics, Inc., H2 2016
  • Treatment Resistant Depression - Pipeline by Reviva Pharmaceuticals Inc., H2 2016
  • Treatment Resistant Depression - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
  • Treatment Resistant Depression - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Treatment Resistant Depression - Dormant Projects, H2 2016
  • Treatment Resistant Depression - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Treatment Resistant Depression, H2 2016
  • Number of Products under Development for Treatment Resistant Depression - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top